Search results for " cardiovascular"

showing 10 items of 6790 documents

The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classificatio…

2016

AbstractThe IASLC Staging and Prognostic Factors Committee has collected a new database of 94,708 cases donated from 35 sources in 16 countries around the globe. This has now been analysed by our statistical partners at Cancer Research And Biostatistics and, in close collaboration with the members of the committee proposals have been developed for the T, N, and M categories of the 8th edition of the TNM Classification for lung cancer due to be published late 2016. In this publication we describe the methods used to evaluate the resultant Stage groupings and the proposals put forward for the 8th edition.

0301 basic medicinePulmonary and Respiratory Medicinemedicine.medical_specialtyPathologyLung NeoplasmsStagingMedizinPrognostic factors1102 Cardiovascular Medicine And HaematologyLung cancer; Prognostic factors; Staging03 medical and health sciences0302 clinical medicineSeer programmedicineHumansOncology & CarcinogenesisStage (cooking)Lung cancerNeoplasm Stagingbusiness.industryGeneral surgeryInternational Association for the Study of Lung Cancer Staging and Prognostic Factors Committee Advisory Boards and Participating Institutions1103 Clinical SciencesPrognosismedicine.diseaseInternational Association for the Study of Lung Cancer Staging and Prognostic Factors Committee Advisory Boards and Participating Institutions030104 developmental biologyOncology030220 oncology & carcinogenesisNeoplasm stagingBiostatisticsLung cancer stagingLung cancerbusinessSEER Program
researchProduct

The Culpability of Respiratory Viruses in Pneumonia-Related Acute Respiratory Failure

2018

0301 basic medicinePulmonary and Respiratory Medicinemedicine.medical_specialtybusiness.industrymedia_common.quotation_subject030106 microbiologyMEDLINECritical Care and Intensive Care Medicinemedicine.disease03 medical and health sciencesPneumonia0302 clinical medicineJurymedicineAcute respiratory failure030212 general & internal medicineRespiratory systemCardiology and Cardiovascular MedicineIntensive care medicinebusinessmedia_commonCulpabilityChest
researchProduct

Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)

2021

Atherosclerotic cardiovascular disease (ASCVD) and consequent acute coronary syndromes (ACS) are substantial contributors to morbidity and mortality across Europe. Much of these diseases burden is modifiable, in particular by lipid-lowering therapy (LLT). Current guidelines are based on the sound premise that with respect to low density lipoprotein cholesterol (LDL-C), “lower is better for longer”, and the recent data have strongly emphasized the need of also “the earlier the better”. In addition to statins, which have been available for several decades, the availability of ezetimibe and inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9) are additional very effective approa…

0301 basic medicineRMmedicine.medical_specialtyCombination therapyPCSK9 inhibitoreffectivenessTreatment goalsLipid-lowering therapy03 medical and health sciences0302 clinical medicineEzetimibemedicineHumansAcute Coronary SyndromeCombination therapyIntensive care medicinePharmacologyStatins.business.industryAtherosclerotic cardiovascular diseaseAnticholesteremic AgentsPCSK9StatinsEffectiveneDisease ManagementAtherosclerosisEzetimibeLipids030104 developmental biologyPCSK9 inhibitors030220 oncology & carcinogenesisPosition paperSafetybusinessVery high riskmedicine.drug
researchProduct

Noncoding RNAs in Critical Limb Ischemia

2020

Peripheral artery disease, caused by chronic arterial occlusion of the lower extremities, affects over 200 million people worldwide. Peripheral artery disease can progress into critical limb ischemia (CLI), its more severe manifestation, which is associated with higher risk of limb amputation and cardiovascular death. Aiming to improve tissue perfusion, therapeutic angiogenesis held promise to improve ischemic limbs using delivery of growth factors but has not successfully translated into benefits for patients. Moreover, accumulating studies suggest that impaired downstream signaling of these growth factors (or angiogenic resistance) may significantly contribute to CLI, particularly under h…

0301 basic medicineRNA UntranslatedAngiogenesisCritical IllnessNeovascularization PhysiologicDisease030204 cardiovascular system & hematologyBioinformaticsArticlePeripheral Arterial Disease03 medical and health sciences0302 clinical medicineIschemiaRisk FactorsmicroRNADiabetes MellitusAnimalsHumansMedicineTherapeutic angiogenesisProgenitor cellHypoxiaInflammationbusiness.industryStem CellsHemodynamicsCritical limb ischemiaHypoxia (medical)Prognosisbody regions030104 developmental biologyGene Expression RegulationRegional Blood FlowArteriogenesismedicine.symptomCardiology and Cardiovascular MedicinebusinessSignal TransductionArteriosclerosis, Thrombosis, and Vascular Biology
researchProduct

Efficacy and Safety of Zofenopril Versus Ramipril in the Treatment of Myocardial Infarction and Heart Failure: A Review of the Published and Unpublis…

2018

Zofenopril is a lipophilic, sulfhydryl group-containing angiotensin-converting enzyme (ACE)-inhibitor, characterized by wide tissue distribution, long duration of action, and pleiotropic effects on endothelial dysfunction. Its clinical efficacy and safety have been described in the four randomized controlled trials of the SMILE program, which globally enrolled more than 3600 patients in post-acute myocardial infarction (AMI) setting. The SMILE-4 study specifically selected patients with left ventricular dysfunction at admission, and compared the effects of zofenopril or ramipril in combination with acetylsalicylic acid (ASA). Zofenopril demonstrated its superiority over ramipril in reducing…

0301 basic medicineRamiprilmedicine.medical_specialtyCaptoprilPopulationMyocardial InfarctionCardiologyAngiotensin-Converting Enzyme InhibitorsHeart failureReviewAcute myocardial infarction030204 cardiovascular system & hematologylaw.inventionZofenopril03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRandomized controlled trialDouble-Blind MethodRamiprillawInternal medicineAcute myocardial infarction; Angiotensin-converting enzyme inhibitors; Cardiology; Heart failure; Left ventricular dysfunction; Ramipril; Zofenopril; Pharmacology (medical)MedicineHumansPharmacology (medical)Myocardial infarctioneducationRandomized Controlled Trials as Topiceducation.field_of_studyLeft ventricular dysfunctionEjection fractionbusiness.industryGeneral Medicinemedicine.diseaseZofenopril030104 developmental biologyTreatment OutcomechemistryAngiotensin-converting enzyme inhibitorHeart failureCardiologyNumber needed to treatbusinessmedicine.drug
researchProduct

Polyvascular disease: A narrative review of current evidence and a consideration of the role of antithrombotic therapy.

2020

Abstract Background and aims Polyvascular disease (PVD) affects approximately 20% of patients with atherosclerosis and is a strong independent risk factor for ischemic outcomes. However, guidelines do not address screening or treatment for PVD, and there have been no PVD-specific trials. We reviewed subgroup analyses of large randomized controlled trials of more intense antithrombotic therapy to determine whether increased intensity of therapy improved ischemic outcomes in patients with PVD. Methods MEDLINE, MEDLINE in-Process, EMBASE, and the Cochrane Library were queried for randomized controlled trials larger than 5000 patients evaluating secondary prevention therapies in patients with c…

0301 basic medicineRelative risk reductionmedicine.medical_specialtyPopulationCoronary Artery Disease030204 cardiovascular system & hematologyCochrane Librarylaw.invention03 medical and health sciencesPeripheral Arterial Disease0302 clinical medicineRandomized controlled trialFibrinolytic AgentslawRisk FactorsInternal medicineAntithromboticmedicineHumansRisk factoreducationeducation.field_of_studybusiness.industryAbsolute risk reductionAtherosclerosis030104 developmental biologyRelative riskCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation InhibitorsAtherosclerosis
researchProduct

Diagnostic and Prognostic Relevance of Red Blood Cell Distribution Width for Vascular Aging and Cardiovascular Diseases.

2019

Evidence suggests association of red blood cell distribution width (RDW) with cardiovascular diseases (CVDs). On the contrary, we underline that the sole RDW values cannot represent a valid CVD biomarker. High RDW values are expression of biological effects of a lot of both endogenous and exogenous factors (i.e., age, sex, genetic background, inflammation, hormones, drugs, diet, exercise, hematological analyzers, and ranges of values), modulating the biology and physiology of erythrocytes. Thus, the singular monitoring of RDW cannot be used to predict cardiovascular disorders. Accordingly, we have reviewed the evidence for potential relationship of RDW values with alterations in the cardiov…

0301 basic medicineSenescenceErythrocyte Indicescirculating endothelial progenitor cells and nucleated red blood cellAgingleukocyte telomere lengthsInflammationDiseaseBioinformaticsEpigenesis Geneticleukocyte telomere length03 medical and health sciencesCVDs; RDW; circulating endothelial progenitor cells and nucleated red blood cells; leukocyte telomere lengths; vascular aging; Aging; Biomarkers; Cardiovascular Diseases; Epigenesis Genetic; Humans; Prognosis; Erythrocyte Indices0302 clinical medicineGeneticmedicineRDW; CVDs; vascular ageing; leukocyte telomere lengths; circulating endothelial progenitor cells and nucleated red blood cells.Settore MED/05 - Patologia ClinicaRDWHumansCVDsProgenitor cellvascular ageingbusiness.industryNucleated Red Blood CellRed blood cell distribution widthCVDPrognosisSettore MED/23030104 developmental biologyvascular agingCardiovascular DiseasesBiomarker (medicine)Geriatrics and Gerontologymedicine.symptombusiness030217 neurology & neurosurgerycirculating endothelial progenitor cells and nucleated red blood cellsBiomarkersHormoneEpigenesisRejuvenation research
researchProduct

Mediterranean nutraceutical foods: Strategy to improve vascular ageing.

2015

Ageing is characterized by a decline in all systemic functions. A greater susceptibility to apoptosis and senescence may contribute to proliferative and functional impairment of endothelial progenitor cells. They play an important role in neo-angiogenesis and endothelial repair. Vascular ageing is associated with changes in the structure and functions of vessels' wall. There are many possible causes of this damage. For sure, inflammation and oxidative stress play a fundamental role in the pathogenesis of endothelial dysfunction, commonly attributed to a reduced availability of nitric oxide. Inflammageing, the chronic low-grade inflammation that characterizes elderly people, aggravates vascu…

0301 basic medicineSenescencePathologymedicine.medical_specialtyAgingInflammationDisease030204 cardiovascular system & hematologyBioinformaticsmedicine.disease_causeDiet MediterraneanEndothelial progenitor cellPathogenesis03 medical and health sciences0302 clinical medicineNutraceuticalmedicineHumansVascular DiseasesEndothelial dysfunctionEndothelial Progenitor CellsSettore MED/04 - Patologia Generalebusiness.industryVascular ageingmedicine.diseaseInflammageing030104 developmental biologyAgeingNutraceuticalEndothelium Vascularmedicine.symptombusinessOxidative stressDevelopmental BiologyMechanisms of ageing and development
researchProduct

Renal Programming by Transient Postnatal Overfeeding: The Role of Senescence Pathways

2020

Background: Early nutrition influences the risk of Chronic Kidney Diseases development in adulthood. Mechanisms underlying the early programming of altered renal function remain incompletely understood. This study aims at characterizing the role of cell senescence pathways in early programming of Chronic Kidney Disease after transient postnatal overfeeding. Material and Methods: Reduced litters of 3 mice pups and standard litters of 10 mice pups were obtained to induce overfed animals during lactation and control animals, respectively. Animals were sacrificed at 24 days (weaning) or at 7 months of life (adulthood). Body weight, blood pressure, kidney weight, and glomerular count were assess…

0301 basic medicineSenescencekidneymedicine.medical_specialtyPhysiologyRenal function030204 cardiovascular system & hematologyprogramming[SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrologylcsh:Physiology03 medical and health sciencesovernutrition0302 clinical medicineOvernutritionPhysiology (medical)Internal medicineLactationmedicineWeaningOriginal Research2. Zero hungerKidneypostnatal overfeedinglcsh:QP1-981biologySirtuin 1medicine.disease[SDV.MHEP.UN] Life Sciences [q-bio]/Human health and pathology/Urology and Nephrologychronic kidney disease; developmental origins of health and disease; kidney; overnutrition; postnatal overfeeding; programming[SDV.AEN] Life Sciences [q-bio]/Food and Nutrition030104 developmental biologymedicine.anatomical_structureEndocrinologybiology.proteindevelopmental origins of health and disease[SDV.AEN]Life Sciences [q-bio]/Food and Nutritionchronic kidney diseaseKidney diseaseFrontiers in Physiology
researchProduct

Anti-PCSK9 treatment: is ultra-low low-density lipoprotein cholesterol always good?

2018

Anti-PCSK9 (proprotein convertase subtilisin kexin 9) monoclonal antibodies (Mab) are novel, potent lipid-lowering drugs. They demonstrated to improve the lipid profile in high cardiovascular risk patients. Anti-PCSK9 Mab inhibit the targeted low-density lipoprotein (LDL)-receptor degradation induced by PCSK9 protein and are able to reduce LDL cholesterol (LDL-C) levels on top of conventional lipid-lowering therapy. Though these drugs proved to be very safe in the short-term, little is known about the possible long-term effects, due to the short period of their marketing. The genetic low cholesterol syndromes (LCS) represent the natural models of the lipid-lowering anti-PCSK9 therapy, and a…

0301 basic medicineSerine Proteinase InhibitorsTime FactorsPhysiologymedicine.drug_class030204 cardiovascular system & hematologyPharmacologyMonoclonal antibodyRisk Assessment03 medical and health sciencesPCSK9 Genechemistry.chemical_compound0302 clinical medicineRisk FactorsPhysiology (medical)Diabetes mellitusmedicineAnimalsHumansDyslipidemiasmedicine.diagnostic_testbusiness.industryCholesterolPCSK9Anticholesteremic AgentsPCSK9 InhibitorsAntibodies MonoclonalCholesterol LDLmedicine.diseaseFatty LiverHypocholesterolemia030104 developmental biologyTreatment OutcomechemistryDiabetes Mellitus Type 2lipids (amino acids peptides and proteins)Proprotein Convertase 9Cardiology and Cardiovascular MedicineLipid profilebusinessCognition DisordersBiomarkersLipoproteinCardiovascular research
researchProduct